Clinical applications of PD-L1 bioassays for cancer immunotherapy

[1]  F. Hirsch,et al.  Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  S. Kobayashi,et al.  Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  E. Hsueh,et al.  Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response , 2017, Biomarker Research.

[4]  Z. Shao,et al.  PD‐L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy , 2017, International journal of cancer.

[5]  P. Sidaway.  Urological cancer: Atezolizumab: an alternative to cisplatin? , 2017, Nature Reviews Clinical Oncology.

[6]  D. Rimm,et al.  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.

[7]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Y. Hosomi,et al.  High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. , 2017, Lung cancer.

[10]  P. Sidaway.  Bladder cancer: Atezolizumab: an alternative to cisplatin? , 2017, Nature Reviews Urology.

[11]  Jinghui Wang,et al.  The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma , 2017, Oncotarget.

[12]  S. Fröhling,et al.  PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma , 2017, Oncoimmunology.

[13]  R. Yuan,et al.  PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective , 2017, Journal of Hematology & Oncology.

[14]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[15]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[16]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[17]  C. Boeckx,et al.  Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system , 2017, Histopathology.

[18]  Richard Pazdur,et al.  An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies , 2016, Clinical Cancer Research.

[19]  C. Sotiriou,et al.  Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer , 2016, Oncoimmunology.

[20]  William A. Hammond,et al.  Emerging therapeutic agents for lung cancer , 2016, Journal of Hematology & Oncology.

[21]  L. Schwartz,et al.  High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy , 2016, Journal of Hematology & Oncology.

[22]  Guoqiang Chen,et al.  CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling , 2016, Journal of Hematology & Oncology.

[23]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[24]  M. Dolled-Filhart,et al.  Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. , 2016, Archives of pathology & laboratory medicine.

[25]  Nicole Schechter,et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma , 2016, Diagnostic Pathology.

[26]  G. Linette,et al.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[27]  Donnell,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Hegde,et al.  Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Yi-long Wu,et al.  Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial , 2016, Journal of Hematology & Oncology.

[30]  E. Hsueh,et al.  Novel melanoma therapy , 2016, Experimental Hematology & Oncology.

[31]  J. Stebbing,et al.  Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy , 2016, Oncoimmunology.

[32]  Haruyasu Murakami,et al.  Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors , 2016, Investigational New Drugs.

[33]  Jacquelyn Smith,et al.  Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N , 2016, Diagnostic Pathology.

[34]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[35]  O. Abdel-Rahman.  Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. , 2016, Critical reviews in oncology/hematology.

[36]  Yih-Leong Chang,et al.  Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. , 2016, European journal of cancer.

[37]  P. Aguiar,et al.  The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. , 2016, Immunotherapy.

[38]  A. Russo,et al.  PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis , 2016, Oncotarget.

[39]  A. Mansfield,et al.  Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer , 2015, Clinical Cancer Research.

[40]  M. Socinski,et al.  Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma , 2015, Experimental Hematology & Oncology.

[41]  Xiaoling Zhang,et al.  Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[42]  H. Asamura,et al.  Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. , 2015, Clinical lung cancer.

[43]  Yijun Tian,et al.  Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer , 2015, Journal of Hematology & Oncology.

[44]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[45]  Ming-Sound Tsao,et al.  Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  S. M. Leong,et al.  Sampling circulating tumor cells for clinical benefits: how frequent? , 2015, Journal of Hematology & Oncology.

[47]  Xiaoling Chen,et al.  Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics , 2015, Thoracic cancer.

[48]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[49]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[50]  K. Tarte,et al.  High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial , 2014, Leukemia.

[51]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[52]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[53]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[54]  Zhen-hua Hu,et al.  Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. , 2011, Cytokine.

[55]  J. Cheville,et al.  Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma , 2011, Clinical Cancer Research.

[56]  Reena Philip,et al.  US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. , 2011, Bioanalysis.

[57]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[58]  J. Bonnefoy,et al.  Soluble CD86 is a costimulatory molecule for human T lymphocytes. , 2000, Immunity.

[59]  M. Oaks,et al.  Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease , 2000, The Journal of Immunology.

[60]  M. Oaks,et al.  A native soluble form of CTLA-4. , 2000, Cellular immunology.

[61]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  P. Hegde,et al.  Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab , 2016 .

[63]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.